Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer

• Main Authors: Eszter Molnár (Author), Marcell Baranyi (Author), Krisztina Szigeti (Author), Luca Hegedűs (Author), Fanni Bordás (Author), Zsófia Gábriel (Author), Gréta Petényi (Author), József Tóvári (Author), Balázs Hegedűs (Author), József Tímár (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history of KRAS m...